Journal of International Obstetrics and Gynecology

Journal of International Obstetrics and Gynecology ›› 2016, Vol. 43 ›› Issue (4): 407-411.

• 综述 • Previous Articles     Next Articles

Progress of Molecular Targeted Therapy in Ovarian Cancer

YANG Mei-lin，LI Jian，ZHANG Ting-zhang，XU Cong-jian   

  1. Department of Obstetrics and Gynecology，Xiamen Chang Gung Hospital，Xiamen 350200，China（YANG Mei-lin，LI Jian，ZHANG Ting-zhang）；Department of Obstetrics and Gynecology，Gynecologic Cancer Research Center，Taoyuan Branch Hospital of Chang Gung Memorial Hospital，Taoyuan，Taiwan Province，China（ZHANG Ting-zhang）；Obstetrics and Gynecology Hospital，Department of Obstetrics and Gynecology of Shanghai Medical School，Fudan University，Shanghai 200011，China（XU Cong-jian）；Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases，Shanghai 200433，China（XU Cong-jian）；Institutes of Biomedical Sciences，Fudan University，Shanghai 200032，China（XU Cong-jian）
  • Received:1900-01-01 Revised:1900-01-01 Published:2016-08-15 Online:2016-08-15
  • Contact: LI Jian

PDF (PC)

5793

Abstract: Ovarian cancer is still the leading cause of death from gynecological caner. Chemotherapy usually shows effectiveness in initial treatment of ovarian cancer, but resistance and toxicities increase over time which limits its use in recurrent cases. Targeted therapy offers a new treatment of ovarian cancer and some impressive breakthroughs have been achieved. Especially in the recurrent and resistant ovarian cancer, targeted therapy can prolong the progression free survival that make up for the deficiency of chemotherapy. Among them, antiangiogenic therapy and PARP inhibitors have been gradually applied in clinical treatment. Besides, personalized medicine could probably be realized in the future through biomarker profiles in targeted therapy. We here summarize drugs in targeted therapy of ovarian cancer, describe the prospects of biomarkers and define the role of molecular targeted therapy in the treatment of ovarian cancer.